[Long-term administration study of propiverine hydrochloride (BUP-4 tablets) in pollakiuria and urinary incontinence].
The safety and efficacy of one-year administration of propiverine hydrochloride (BUP-4 tablets) were assessed in facilities affiliated with the Department of Urology of Yokohama City University School of Medicine. Changes in subjective symptoms showed significant improvement in mean frequency of urination in the daytime from 10.3 +/- 4.0 times before administration to 7.1 +/- 2.9 times 1 year after the start of administration, in mean frequency of voiding at night from 4.2 +/- 1.7 times to 2.1 +/- 1.1 times and in mean incidence of urinary incontinence from 2.9 +/- 2.1 times to 0.7 +/- 1.0 times. The final degree of overall improvement rate was 82.0% (41/50 cases). Adverse effects were observed 26 times in 22 patients, the incidence being 15.6% (22/141 cases). They consisted of digestive symptoms in 9.9% (6 events of dry mouth, 4 of constipation, 2 of abdominal discomfort, 2 of diarrhea and 1 of gastritis), urinary tract symptoms in 3.5% (4 of dysuria and 1 of residual urine), abnormal laboratory findings in 1.4% (increase in glutamic-oxaloacetic transaminase, glutamic-pyruvic transaminase or lactate dehydrogenase levels) and others (1.4%). These results provide further evidence of the safety and efficacy of propiverine hydrochloride (BUP-4 tablets) even when administered for a long-term in the treatment of patients with pollakiuria and urinary incontinence.
Noguchi
K
K
Department of Urology, Yokohama City University School of Medicine.
Masuda
M
M
Noguchi
S
S
Kubota
Y
Y
Hosaka
M
M
Senga
Y
Y
Sano
K
K
Miyai
K
K
Kanno
H
H
Kitami
K
K
Fujinami
K
K
Miura
T
T
Kondo
I
I
Kawasaki
C
C
Moriyama
M
M
Hara
Y
Y
Ida
T
T
Fukuoka
H
H
Nakagawa
J
J
Kitajima
N
N
Fukuda
M
M
Satomi
Y
Y
Takahashi
T
T
Yamaguchi
T
T
Shiozaki
H
H
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001561:Benzilates / Q000008:administration & dosage* / Q000009:adverse effects; D002121:Calcium Channel Blockers / Q000008:administration & dosage* / Q000009:adverse effects; D018680:Cholinergic Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D004066:Digestive System Diseases / Q000139:chemically induced; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010276:Parasympatholytics / Q000008:administration & dosage* / Q000009:adverse effects; D011141:Polyuria / Q000188:drug therapy*; D013607:Tablets; D013997:Time Factors; D016896:Treatment Outcome; D014549:Urinary Incontinence / Q000188:drug therapy*; D014570:Urologic Diseases / Q000139:chemically induced
D001561:Benzilates; D002121:Calcium Channel Blockers; D018680:Cholinergic Antagonists; D010276:Parasympatholytics; D013607:Tablets; C015586:propiverine